Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044954 · ClinicalTrials.gov registry record · Phase 2
Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00044954: Completed Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT00044954 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044954, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining total-body irradiation with fludarabine and donor peripheral stem cell transplantation in treating patients who have hematologic cancer.
Interventions
- DRUG fludarabine phosphate
- PROCEDURE allogeneic bone marrow transplantation
- DRUG cyclosporine
- DRUG mycophenolate mofetil
- BIOLOGICAL therapeutic allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00044954 record still lists
NCT00044954 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which fludarabine phosphate is the first listed.
NCT00044954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044954 about?
NCT00044954 is a clinical study titled "Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses ...
What is the current status of trial NCT00044954?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-11. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00044954?
The interventions under investigation include: fludarabine phosphate (DRUG), allogeneic bone marrow transplantation (PROCEDURE), cyclosporine (DRUG), mycophenolate mofetil (DRUG), therapeutic allogeneic lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00044954?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia